Zymeworks Inc

96 articles with Zymeworks Inc

• Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

  1/17/2019

  - Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials - Zymeworks to receive milestone payment of US$8.0 million for this second IND submission - Lilly is one of eight pharma partners; INDs by others anticipated - Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion

• Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

  1/6/2019

  Zymeworks Inc. today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.

• Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

  12/8/2018

  ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates (ADCs)

• Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

  11/14/2018

  ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types

• Zymeworks to Present at Upcoming November 2018 Investor Conferences

  11/7/2018

  Zymeworks Inc. today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

• ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

  11/6/2018

  ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.

• Zymeworks Reports Financial Results for the Third Quarter of 2018

  11/6/2018

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “

• Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

  10/30/2018

  ​Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers

• Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

  10/23/2018

  The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms

• Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration.

  10/23/2018

  Zymeworks Inc. and LEO Pharma A/S have entered into a licensing and research collaboration to discover and develop bispecific antibodies.

• Zymeworks to Webcast R&D Briefing on October 11, 2018

  10/4/2018

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.

• Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference

  9/25/2018

  Zymeworks Inc. today announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY.

• Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

  9/19/2018

  Zymeworks Inc. today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer.

• Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

  9/4/2018

  Sept. 4, 2018 21:00 UTC Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collabora

• Zymeworks to Present at 13th Annual Wells Fargo Healthcare Conference

  8/29/2018

  Zymeworks Inc. today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

• 

  Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

  6/20/2018

  The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.

• Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

  6/8/2018

  Zymeworks Inc. is pleased to announce the detailed voting results on the items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018

• Zymeworks Announces Pricing of Public Offering of 5,400,000 Common Shares

  6/7/2018

  Zymeworks Inc. announced the pricing of its previously- announced underwritten public offering (the “Offering”) of 5,400,000 common shares at a price to the public of US$15.75 per common share

• Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

  6/6/2018

  Zymeworks Inc. has filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated May 24, 2018

• Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

  6/1/2018

  Zymeworks Inc. announced the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center.